Corbus Pharmaceuticals Holdings (CRBP) Capital Expenditures (2014 - 2024)

Corbus Pharmaceuticals Holdings has reported Capital Expenditures for 11 years, with the latest figure at $1000.0 in Q2 2024.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $1000.0 in Q2 2024; TTM through Mar 2025 was $1000.0, a 100.64% increase from a year earlier, with the FY2024 full-year figure at -$212000.0, down 471.93% from the prior year.
• Capital Expenditures was $1000.0 for Q2 2024 at Corbus Pharmaceuticals Holdings, up from -$213000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $463605.0 in Q1 2020, with the low at -$213000.0 in Q1 2024.
• Average Capital Expenditures over 5 years is $39711.2, with a median of $14811.5 recorded in 2020.
• The largest YoY upside for Capital Expenditures was 529.77% in 2020 against a maximum downside of 104.03% in 2020.
• Over 5 years, Capital Expenditures stood at -$52086.0 in 2020, then jumped by 204.0% to $54172.0 in 2021, then slumped by 75.17% to $13449.0 in 2022, then declined by 18.21% to $11000.0 in 2023, then sank by 90.91% to $1000.0 in 2024.
• The last three Capital Expenditures figures came in at $1000.0 (Q2 2024), -$213000.0 (Q1 2024), and $11000.0 (Q4 2023), per Business Quant data.